John C. Pesko

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

Targeted protein degradation: advances in drug discovery and clinical practice

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study